It is estimated that 80 to 90% of drugs under development never make it to the marketplace due to insufficient clinical activity, unacceptable toxicity, rapid appearance of drug resistance, or other factors that should be, at least partially, predictable from preclinical testing. This new text asks the question, "How can we use computational method

chapter 2|28 pages

Physiological Pharmacokinetic Modeling

chapter 3|22 pages

Interspecies Scaling

chapter 4|24 pages

Prediction of Drug Metabolism and Toxicity

chapter 5|32 pages

Pharmacodynamic Modeling

chapter 6|30 pages

Cytokinetic Modeling

chapter 7|30 pages

Prediction of Drug Resistance

chapter 8|22 pages

Conclusions: The Virtual Clinical Trial